KALV
Income statement / Annual
Last year (2024), KalVista Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, KalVista Pharmaceuticals, Inc.'s net income was -$126.64 M.
See KalVista Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
04/30/2015 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$12.69 M |
$12.69 M |
$16.13 M |
$8.39 M |
$1.50 M |
$2.13 M |
$1.80 M |
Cost of Revenue |
$86.17 M
|
$802,000.00
|
$743,000.00
|
$651,000.00
|
$40,194.00
|
$35,021.00
|
$18,237.00
|
$12,666.00
|
$14,661.00
|
$8,285.00
|
Gross Profit |
-$86.17 M
|
-$802,000.00
|
-$743,000.00
|
$12.04 M
|
$12.65 M
|
$16.09 M
|
$8.38 M
|
$1.49 M
|
$2.12 M
|
$1.80 M
|
Gross Profit Ratio |
0
|
0
|
0
|
0.95
|
1
|
1
|
1
|
0.99
|
0.99
|
1
|
Research and Development Expenses |
$86.17 M
|
$80.28 M
|
$70.17 M
|
$41.29 M
|
$40.19 M
|
$35.02 M
|
$18.24 M
|
$12.67 M
|
$14.66 M
|
$8.29 M
|
General & Administrative Expenses |
$54.28 M
|
$30.60 M
|
$26.45 M
|
$16.64 M
|
$13.03 M
|
$10.93 M
|
$8.86 M
|
$11.18 M
|
$2.65 M
|
$1.61 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$54.28 M
|
$30.60 M
|
$26.45 M
|
$16.64 M
|
$13.03 M
|
$10.93 M
|
$8.86 M
|
$11.18 M
|
$2.65 M
|
$1.61 M
|
Other Expenses |
-$86.17 M
|
$15.64 M
|
$14.72 M
|
$9.93 M
|
$9.83 M
|
$7.68 M
|
$4.39 M
|
$2.33 M
|
$2.03 M
|
$844,000.00
|
Operating Expenses |
$54.28 M
|
$110.87 M
|
$96.61 M
|
$57.92 M
|
$53.22 M
|
$45.95 M
|
$27.10 M
|
$23.84 M
|
$17.31 M
|
$9.89 M
|
Cost And Expenses |
$140.45 M
|
$110.87 M
|
$96.61 M
|
$57.92 M
|
$53.22 M
|
$45.95 M
|
$27.10 M
|
$23.84 M
|
$17.31 M
|
$9.89 M
|
Interest Income |
$0.00
|
$2.23 M
|
$1.09 M
|
$903,000.00
|
$1.83 M
|
$1.40 M
|
$82,000.00
|
$36,000.00
|
$50,000.00
|
$19,000.00
|
Interest Expense |
$0.00
|
$0.00
|
$1.09 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$816,000.00
|
$802,000.00
|
$743,000.00
|
$651,000.00
|
$525,000.00
|
$378,000.00
|
$180,000.00
|
$40,000.00
|
$133,000.00
|
$38,000.00
|
EBITDA |
-$134.28 M |
-$92.11 M |
-$81.60 M |
-$45.59 M |
-$40.02 M |
-$29.44 M |
-$18.53 M |
-$22.30 M |
-$15.15 M |
-$8.05 M |
EBITDA Ratio |
0
|
0
|
0
|
-4.59
|
-3.12
|
-1.83
|
-2.02
|
-15.74
|
-7.88
|
-4.46
|
Operating Income Ratio |
0
|
0
|
0
|
-4.56
|
-3.19
|
-1.85
|
-2.23
|
-14.85
|
-7.12
|
-4.48
|
Total Other Income/Expenses Net |
$5.35 M
|
$17.96 M
|
$14.27 M
|
$11.68 M
|
$11.29 M
|
$9.13 M
|
$2.90 M
|
$3.74 M
|
$3.75 M
|
$863,000.00
|
Income Before Tax |
-$135.10 M
|
-$92.91 M
|
-$82.34 M
|
-$46.24 M
|
-$29.24 M
|
-$20.69 M
|
-$15.81 M
|
-$18.60 M
|
-$11.44 M
|
-$7.23 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
-3.64
|
-2.3
|
-1.28
|
-1.88
|
-12.37
|
-5.36
|
-4.01
|
Income Tax Expense |
-$8.45 M
|
-$18.05 M
|
-$13.83 M
|
-$1.75 M
|
-$124,000.00
|
$124,000.00
|
-$1.33 M
|
-$5.11 M
|
-$5.41 M
|
-$863,000.00
|
Net Income |
-$126.64 M
|
-$74.85 M
|
-$68.51 M
|
-$44.49 M
|
-$29.12 M
|
-$20.82 M
|
-$15.81 M
|
-$18.60 M
|
-$11.44 M
|
-$7.23 M
|
Net Income Ratio |
0
|
0
|
0
|
-3.51
|
-2.29
|
-1.29
|
-1.88
|
-12.37
|
-5.36
|
-4.01
|
EPS |
-3.44 |
-2.68 |
-2.8 |
-2.33 |
-1.64 |
-1.38 |
-1.53 |
-1.92 |
-2.4 |
-6.17 |
EPS Diluted |
-3.44 |
-2.68 |
-2.8 |
-2.33 |
-1.64 |
-1.38 |
-1.53 |
-1.92 |
-2.4 |
-6.17 |
Weighted Average Shares Out |
$36.79 M
|
$27.89 M
|
$24.47 M
|
$19.09 M
|
$17.75 M
|
$15.08 M
|
$10.32 M
|
$9.71 M
|
$4.77 M
|
$1.17 M
|
Weighted Average Shares Out Diluted |
$36.79 M
|
$27.89 M
|
$24.47 M
|
$19.09 M
|
$17.75 M
|
$15.08 M
|
$10.32 M
|
$9.71 M
|
$4.77 M
|
$1.17 M
|
Link |
|
|
|
|
|
|
|
|
|
|